Lixte Biotechnology Holdings, Inc.
LIXT
$5.16
$0.122.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 206.27% | 181.64% | -10.55% | -27.40% | -34.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 197.39% | 83.20% | -23.23% | -26.89% | -40.20% |
| Operating Income | -197.39% | -83.20% | 23.23% | 26.89% | 40.20% |
| Income Before Tax | -311.83% | -100.85% | 23.27% | 26.94% | 40.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -311.83% | -100.85% | 23.27% | 26.94% | 40.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -311.83% | -100.85% | 23.27% | 26.94% | 40.16% |
| EBIT | -197.39% | -83.20% | 23.23% | 26.89% | 40.20% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -17.26% | 24.93% | 36.56% | 33.51% | 40.07% |
| Normalized Basic EPS | -16.43% | 26.79% | 36.56% | 33.53% | 40.08% |
| EPS Diluted | -17.26% | 24.93% | 36.56% | 33.51% | 40.07% |
| Normalized Diluted EPS | -16.43% | 26.79% | 36.56% | 33.53% | 40.08% |
| Average Basic Shares Outstanding | 253.83% | 174.36% | 20.95% | 9.88% | -0.16% |
| Average Diluted Shares Outstanding | 253.83% | 174.36% | 20.95% | 9.88% | -0.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |